GlassScriptPhysician profile
James H Paxton
NPI 1063622793
$9,771.33
in general payments reported to CMS, 2019-2025
11 companies · $3,248 in 2025
The $3,248 reported for 2025 was more than what 97% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2023: $6,204 · 2024: $118 · 2025: $3,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,785 · Grant: $2,000 · Food and Beverage: $1,802 · Travel and Lodging: $982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,785.00 |
| Grant | $2,000.00 |
| Food and Beverage | $1,802.36 |
| Travel and Lodging | $981.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $5,660.83 | 2023 | |
| Genzyme Corporation | $2,000.00 | 2025 | |
| Aop Health US, LLC | $1,247.70 | 2025 | Rapiblyk |
| Quidel Corporation | $400.00 | 2023 | |
| Abbott Laboratories | $143.01 | 2023 | I-Stat |
| Astrazeneca Pharmaceuticals LP | $117.50 | 2024 | Andexxa |
| Genentech USA, INC. | $102.56 | 2019 | |
| Teleflex LLC | $99.73 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Paxton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.